Publications

32 SCORE publications partners during the first 21 months of the project period.

Peer Reviewed and Published Publications

  1. Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds  Linlin Zhang, McClane Howland, Rolf Hilgenfeld, Marc O Anderson, Scott Eagon. Bioorg Med Chem Lett 2021 Jun 1;41:127990 doi: https://doi.org/10.1016/j.bmcl.2021.127990
  2. The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2   Natacha S. Ogando, Jessika C. Zevenhoven-Dobbe, Yvonne van der Meer, Peter J. Bredenbeek, Clara C. Posthuma, Eric J. Snijder.  J. Journal of Virology Vol. 94, No. 23 doi: https://doi.org/10.1128/JVI.01246-20 
  3. A molecular pore spans the double membrane of the coronavirus replication organelle  Georg Wolff, Ronald W.A.L. Limpens, Jessika C. Zevenhoven-Dobbe, Ulrike Laugks, Shawn Zheng, Anja W. M. de Jong, Roman I. Koning, David A. Agard, Kay Grünewald, Abraham J. Koster, Eric J. Snijder, Montserrat Bárcena Science 2020 Sep 11;369(6509):1395-1398 doi: https://doi.org/10.1126/science.abd3629
  4. Drugs against SARS-CoV-2: What do we know about their mode of action? Coralie Valle, Baptiste Martin, Franck Touret, Ashleigh Shannon, Bruno Canard, Jean-Claude Guillemot, Bruno Coutard, Etienne Decroly. Rev Med Virol. 2020 Aug 11 : e2143  doi: https://doi.org/10.1002/rmv.2143
  5. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. (2020): Science. 368, 409-412. doi: https://doi.org/10.1126/science.abb3405 
  6. A Fluorescence-based High Throughput-Screening assay for the SARS-CoV RNA synthesis complex. Cecilia Eydoux, Veronique Fattorini, Ashleigh Shannon, Thi-Tuyet-Nhung Le, Bruno Didier, Bruno Canard, Jean-Claude Guillemot. J Virol Methods 2021 Feb;288:114013.; doi: https://doi.org/10.1016/j.jviromet.2020.114013 
  7. A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate. Lorena Sanchez Felipe, Thomas Vercruysse, Sapna Sharma, Ji Ma1, Viktor Lemmens Dominique van Looveren, Mahadesh Prasad Arkalagud Javarappa, Robbert Boudewijns, Bert alengier-Devlies, Suzanne F. Kaptein, Laurens Liesenborghs, Carolien De Keyzer, Lindsey Bervoets, Madina Rasulova, Laura Seldeslachts, Sander Jansen, Michael Bright Yakass, Osbourne Quaye, Li-Hsin Li, Xin Zhang, Sebastiaan ter Horst, Niraj Mishra, Lotte Coelmont, Christopher Cawthorne, Koen Van Laere, Ghislain Opdenakker, Greetje Van de Veld, Birgit Weynand, Dirk E. Teuwen, Patrick Matthys,  Johan Neyts.  Nature 590320–325 (2021). doi: https://doi.org/10.1038/s41586-020-3035-9 
  8. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.  Ashleigh Shannon, Barbara Selisko, Nhung-Thi-Tuyet Le, Johanna Huchting, Franck Touret, Géraldine Piorkowski, Véronique Fattorini, François Ferron, Etienne Decroly, Chris Meier, Bruno Coutard, Olve Peersen & Bruno Canard. Nat Comm. 2020 Sep 17;11(1):4682. doi: https://doi.org/10.1038/s41467-020-18463-z 
  9. SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
    Wioletta Rut, Katarzyna Groborz, Linlin Zhang, Xinyuanyuan Sun, Mikolaj Zmudzinski, Bartlomiej Pawlik, Xinyu Wang, Dirk Jochmans, Johan Neyts, Wojciech Młynarski, Rolf Hilgenfeld & Marcin Drag. Nature Chemical Biology volume 17, pages222–228 (2021 October. doi: https://doi.org/10.1038/s41589-020-00689-z 
  10. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity. Suzanne JF Kaptein, Sofie Jacobs, Lana Langendries, Laura Seldeslachts, Sebastiaan ter Horst, Laurens Liesenborghs, Bart Hens, Valentijn Vergote, Elisabeth Heylen, Elke Maas, Carolien De Keyzer, Lindsey Bervoets, Jasper Rymenants, Tina Van Buyten, Hendrik Jan Thibaut, Kai Dallmeier, Robbert Boudewijns, Jens Wouters, Patrick Augustijns, Nick Verougstraete, Christopher Cawthorne, Birgit Weynand, Pieter Annaert, Isabel Spriet, Greetje Vande Velde, Johan Neyts, Joana Rocha-Pereira, Leen Delang. PNAS October 27, 2020 117 (43) 26955-26965; doi: https://doi.org/10.1073/pnas.2014441117 
  11. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamster. Robbert Boudewijns, Hendrik Jan Thibaut, Suzanne J. F. Kaptein, Rong Li, Valentijn Vergote, Laura Seldeslachts, Carolien De Keyzer, Lindsey Bervoets, Sapna Sharma, Johan Van Weyenbergh, Laurens Liesenborghs, Ji Ma, Sander Jansen, Dominique Van Looveren, Thomas Vercruysse, Dirk Jochmans, Xinyu Wang, Erik Martens, Kenny Roose, Dorien De Vlieger, Bert Schepens, Tina Van Buyten, Sofie Jacobs, Yanan Liu, Joan Martí-Carreras, Bert Vanmechelen, Tony Wawina-Bokalanga, Leen Delang, Joana Rocha-Pereira, Lotte Coelmont, Winston Chiu, Pieter Leyssen, Elisabeth Heylen, Dominique Schols, Lanjiao Wang, Lila Close, Jelle Matthijnssens, Marc Van Ranst, Veerle Compernolle, Georg Schramm, Koen Van Laere, Xavier Saelens, Nico Callewaert, Ghislain Opdenakker, Piet Maes, Birgit Weynand, Christopher Cawthorne, Greetje Vande Velde, Zhongde Wang, Johan Neyts, Kai Dallmeier. Nat Comm 11, 5838, 2020; doi: https://doi.org/10.1038/s41467-020-19684-y 
  12. The nucleotide addition cycle of the SARS-CoV-2 polymerase. Subhas Chandra Bera, Mona Seifert, Robert N. Kirchdoerfer, Pauline van Nies, Yibulayin Wubulikasimu, Salina Quack, Flávia S. Papini, Jamie J. Arnold, Bruno Canard, Craig E. Cameron, Martin Depken, David Dulin. Cell Reports. Vol36, Issue 9, 31 Aug 2021, 109650; doi: https://doi.org/10.1016/j.celrep.2021.109650 
  13. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs: a single molecule perspective. Mona Seifert, Subhas Chandra Bera, Pauline van Nies, Robert N. Kirchdoerfer, Ashleigh Shannon, Thi-Tuyet-Nhung Le, Xiangzhi Meng, Hongjie Xia, James M. Wood, Lawrence D. Harris, Flávia S. Papini, Jamie J. Arnold, Steven C. Almo, Tyler L. Grove, Pei-Yong Shi, Yan Xiang, Bruno Canard, Martin Depken, Craig E. Cameron, David Dulin. eLife, 10. ISSN 2050-084X; doi: https://doi.org/10.7554/elife.70968 
  14. In Vitro Activity of Itraconazole Against SARS-CoV-2. Ellen Van Damme, Sandra De Meyer, Denisa Bojkova, Sandra Ciesek, Jindrich Cinatl, Steven De Jonghe, Dirk Jochmans, Pieter Leyssen, Christophe Buyck, Johan Neyts, Marnix Van Loock. J Med Virol. 2021 Jul;93(7):4454-4460; doi: https://doi.org/10.1002/jmv.26917
  15. The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. Rana Abdelnabi, Caroline S. Foo, Suzanne J. F. Kaptein, Xin Zhang, Lana Langendries, Laura Vangeel, Judith Breuer, Juanita Pang, Rachel Williams, Valentijn Vergote, Elisabeth Heylen, Pieter Leyssen, Kai Dallmeier, Lotte Coelmont, Dirk Jochmans, Arnab K. Chatterjee, Steven De Jonghe, Birgit Weynand, Johan Neyts. Lancet vol.27, Oct. 2021, 103595 ; doi: https://doi.org/10.1016/j.ebiom.2021.103595 
  16. The enzymatic activity of the nsp14 exoribonuclease Is critical for replication of MERS-CoV and SARS-CoV-2. Ogando NS, Zevenhoven-Dobbe JC, van der Meer Y, Bredenbeek PJ, Posthuma CC, Snijder EJ. J Virol. (2020) 94(23):e01246-20. doi: https://doi.org/10.1128/JVI.01246-20 
  17. Structure-function analysis of the nsp14 N7-guanine methyltransferase reveals an essential role in betacoronavirus replication. Natacha S. Ogando, Priscila El Kazzi, Jessika C. Zevenhoven-Dobbe, Brenda W. Bontes,  Alice Decombe, Clara C. Posthuma, Volker Thiel, Bruno Canard, François Ferron, Etienne Decroly, Eric J. Snijder. PNAS December 7, 2021 118 (49) e2108709118.  doi: https://doi.org/10.1073/pnas.2108709118 
  18. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. Rana Abdelnabi, Caroline S Foo, Steven De Jonghe, Piet Maes, Birgit Weynand, Johan Neyts. The Journal of Infectious Diseases, Volume 224, Issue 5, 1 September 2021, Pages 749–753, doi: https://doi.org/10.1093/infdis/jiab361
  19. COVID-19 and the intensive care unit: vaccines to the rescue. Kai Dallmeier, Geert Meyfroidt, Johan Neyts. Intensive Care Medicine volume 47, pages 786–789 (2021). doi: https://doi.org/10.1007/s00134-021-06414-1 
  20. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19. Andrea Torneri, Pieter Libin, Joris Vanderlocht, Anne-Mieke Vandamme, Johan Neyts and Niel Hens.BMC Med 18, 191 (2020. doi:  https://doi.org/10.1186/s12916-020-01636-4 
  21. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. Laurens Liesenborghs, Isabel Spriet, Pharm.D Dirk Jochmans, Ann Belmans, Iwein Gyselinck, Laure-Anne Teuwen, Sebastiaan ter Horst, Erwin Dreesen, Tatjana Geukens, Matthias M. Engelen, Ewout Landeloos, Vincent Geldhof, Helga Ceunen, Barbara Debaveye, Bert Vandenberk, Lorenz Van der Linden, Sofie Jacobs, Lana Langendries, Robbert Boudewijns, Thuc Nguyen Dan Do, Winston Chiu, Xinyu Wang. Xin Zhang. Birgit Weynand, Thomas Vanassche, Timothy Devos, Geert Meyfroidt, Wim Janssens, Robin Vos, Pieter Vermeersch, Joost Wauters, Geert Verbeke, Paul De Munter, M.D. Suzanne J.F. Kaptein, Joana Rocha-Pereira, Leen Delang, Eric Van Wijngaerden, Johan Neyts, and Peter Verhamme. EBioMedicine. 2021 Apr; 66: 103288. doi: https://doi.org/10.1016/j.ebiom.2021.103288 
  22. Medical treatment options for COVID-19.Leen Delang and Johan Neyts. Eur Heart J Acute Cardiovasc Care. 2020 Apr 1; 9(3):209-214.doi: https://doi.org/10.1177/2048872620922790 
  23. Structure–function analysis of the nsp14 N7–guanine methyltransferase reveals an essential role in Betacoronavirus replication. Natacha S. Ogando, Priscila El Kazzi, Jessika C. Zevenhoven-Dobbe, Brenda W. Bontes, Alice Decombe, Clara C. Posthuma, Volker Thiel, Bruno Canard, François Ferron, Etienne Decroly, and Eric J. Snijder. PNAS December 7, 2021 118 (49) e2108709118; https://doi.org/10.1073/pnas.2108709118 
  24. Comparative infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian hamsters. Rana Abdelnabi, Robbert Boudewijns, Caroline S. Foo, Laura Seldeslachts, Lorena Sanchez-Felipe, Xin Zhang, Leen Delang, Piet Maes, Suzanne J. F. Kaptein, Birgit Weynand, Greetje Vande Velde, Johan Neyts, Kai Dallmeier. EBioMedicine. 2021 Jun;68:103403. doi: https://doi.org/10.1016/j.ebiom.2021.103403
     

Submitted SCORE publications which have not yet been published.

  1. Preprint. A high-throughput fluorescence polarization assay to discover inhibitors of arenavirus and coronavirus exoribonucleases  Sergio Hernández,  Mikael Feracci, Carolina Trajano De Jesus, Priscila El-Kazzi, Rafik Kaci, Laura Garlatti, Etienne Decroly,  Bruno Canard,  François Ferron,  Karine Alvarez.  bioRxiV doi: https://doi.org/10.1101/2021.04.02.437736
  2. Preprint. Substrate specificity profiling of SARS-CoV-2 main protease enables design of activity-based probes for patient-sample imaging. Rut W., Groborz K., Zhang L., Sun X.,  Zmudzinskia M., Pawlik B., Wang X., Jochmans D., Neyts J., Młynarski W., Hilgenfeld R., Drag M. doi: https://doi.org/10.1101/2020.03.07.981928 
  3. Preprint. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. A. Shannon, B. Selisko, NTT Le, J. Huchting, F. Touret, G. Piorkowski, V. Fattorini, F. Ferron, E. Decroly, C Meier, B. Coutard, O. Peersen, B. Canard. bioRxiv 2020.05.15.098731; doi: https://doi.org/10.1101/2020.05.15.098731 
  4. Preprint. Protein-primed RNA synthesis in SARS-CoVs and structural basis for inhibition by AT-527. Ashleigh Shannon, Véronique Fattorini, Bhawna Sama, Barbara Selisko, Mikael Feracci, Camille Falcou, Pierre Gauffre, Priscila El Kazzi, Etienne Decroly, Nadia Rabah, Karine Alvarez, Cécilia Eydoux, Jean-Claude Guillemot, Françoise Debart, Jean-Jacques Vasseur, Mathieu Noel, Adel Moussa, Steven Good, Kai Lin, Jean-Pierre Sommadossi, Yingxiao Zhu, Xiaodong Yan, Hui Shi, François Ferron, Bruno Canard. bioRxiv 2021.03.23.436564; doi: https://doi.org/10.1101/2021.03.23.436564 
  5. Preprint. Ebselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PLpro and Mpro in in vitro studies. Mikolaj Zmudzinski, Wioletta Rut, Kamila Olech, Jarosław Granda, Mirosław Giurg, Małgorzata Burda-Grabowska, Linlin Zhang, Xinyuanyuan Sun, Zongyang Lv, Digant Nayak, Malgorzata Kesik-Brodacka, Shaun K. Olsen, Rolf Hilgenfeld, Marcin Drag. bioRxiv 2020.08.30.273979; doi: https://doi.org/10.1101/2020.08.30.273979 
  6. Preprint. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-1 2 variants of concern. Rana Abdelnabi, Caroline S. Foo, Dirk Jochmans, Laura Vangeel, Steven De Jonghe, Patrick Augustijns, Raf Mols, Birgit Weynand, Thanaporn Wattanakul, Richard M. Hoglund, Joel Tarning, Charles E. Mowbray, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain, Johan Neyts. doi: https://doi.org/10.1101/2021.11.04.467077 
  7. Preprint. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Laura Vangeel, Steven De Jonghe, Piet Maes, Bram Slechten, Joren Raymenants, Emmanuel André, Johan Neyts, Dirk Jochmans. doi: https://doi.org/10.1101/2021.12.27.474275 
  8. Preprint. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Rana Abdelnabi, Caroline S. Foo, Xin Zhang, Viktor Lemmens, Piet Maes, Bram Slechten, Joren Raymenants, Emmanuel André, Birgit Weynand, Kai Dallemier, Johan Neyts. doi: https://doi.org/10.1101/2021.12.24.474086